Erectile Dysfunction Treatment Guidelines

First-Line Treatment

The American College of Physicians recommends PDE5 inhibitors (sildenafil, vardenafil, tadalafil) as the first-line pharmacologic treatment for erectile dysfunction with strong evidence supporting their efficacy 1, 2
PDE5 inhibitors have demonstrated statistically significant and clinically relevant improvements in sexual intercourse and erectile function in patients with ED, with success rates of 69% compared to 35% with placebo 3
Treatment should begin with conservative dosing of PDE5 inhibitors and titrated to maximum dose if needed, as suggested by the National Comprehensive Cancer Network 4

PDE5 inhibitors are contraindicated in patients taking nitrates due to risk of dangerous hypotension, according to the National Comprehensive Cancer Network 5, 4
Cardiovascular risk assessment is essential before prescribing PDE5 inhibitors, as recommended by the National Comprehensive Cancer Network 4
Patients unable to walk 1 mile in 20 minutes or climb 2 flights of stairs in 20 seconds without symptoms should be referred to a cardiologist before treatment, as suggested by the National Comprehensive Cancer Network 4

The choice of specific PDE5 inhibitor should be based on individual patient preferences, ease of use, cost, and adverse effects profile, as recommended by the American College of Physicians 6, 2
An adequate trial of PDE5i is defined as at least 5 separate occasions at the maximum dose before considering it ineffective, according to the National Comprehensive Cancer Network 4
All patients with erectile dysfunction should be advised on risk factor modification including smoking cessation, weight loss, increasing physical activity, and avoiding excess alcohol consumption, as recommended by the National Comprehensive Cancer Network 5, 4

If PDE5 inhibitors fail, second-line interventions include intraurethral alprostadil suppositories, intracavernous vasoactive drug injection therapy, and vacuum constriction devices, as suggested by the National Comprehensive Cancer Network and the BMJ 4, 7
Penile prosthesis implantation is considered a third-line, definitive intervention, according to the National Comprehensive Cancer Network 4

Hormonal testing is not routinely recommended for all patients with erectile dysfunction; decisions to measure hormone levels should be individualized based on clinical presentation, as recommended by the American College of Physicians 1, 2
Testosterone therapy is not indicated for erectile dysfunction in patients with normal serum testosterone levels, according to the Journal of Urology 8
Other treatments such as trazodone and yohimbine are not recommended for erectile dysfunction based on insufficient evidence, as stated by the Journal of Urology 8

The American College of Physicians recommends individualizing the decision to measure testosterone based on clinical presentation suggesting hormonal abnormality, such as decreased libido, in patients with erectile dysfunction 9, 10
The Princeton III Consensus and International Guidelines recommend measuring testosterone in all men with organic erectile dysfunction, especially those for whom PDE5 inhibitor therapy failed, as supported by the British Society for Sexual Medicine and International Society for Sexual Medicine 11

Testosterone levels should be measured before prescribing PDE5 inhibitors in patients with erectile dysfunction and low libido, as low testosterone is present in 12.5-36% of men with erectile dysfunction and may predict treatment response 9, 11
Cardiovascular risk assessment, including blood pressure, waist circumference and BMI, lipid panel, fasting glucose or HbA1c, and resting electrocardiogram, is essential in patients with erectile dysfunction 11, 12

The American College of Physicians does not recommend routine hormonal blood tests for all erectile dysfunction patients, but suggests individualizing the decision based on clinical presentation 9, 10
PDE5 inhibitor therapy can be initiated immediately without waiting for testosterone results, as long as there are no contraindications, such as nitrate therapy 9, 12
Testosterone supplementation combined with PDE5 inhibitors may improve outcomes in hypogonadal men, though evidence quality is limited 9, 10

Nitrate therapy is an absolute contraindication to PDE5 inhibitors, causing dangerous hypotension 9, 12
Severe hepatic impairment is a contraindication to PDE5 inhibitors, and patients with cardiovascular symptoms or risk factors should be referred to cardiology before treatment 11

Low testosterone is associated with increased all-cause and cardiovascular mortality, and PDE5 inhibitors alone may have reduced efficacy in patients with low testosterone 11
Testosterone therapy is not indicated for erectile dysfunction in men with normal testosterone levels 12